Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, vol.49, pp.1374-403, 2013. ,
A French multicentric longitudinal descriptive study of hepatocellular carcinoma management (the CHANGH cohort): preliminary results, J Hepatol, vol.52, pp.231-233, 2010. ,
clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, vol.56, pp.908-951, 2012. ,
Management of hepatocellular carcinoma, Hepatology, vol.42, pp.1208-1244, 2005. ,
Management of hepatocellular carcinoma: an update, Hepatology, vol.53, pp.1020-1022, 2011. ,
, EASL clinical practical guidelines : management of alcoholic liver disease, J Hepatol, vol.57, pp.399-420, 2012.
Screening for hepatocellular carcinoma in chronic liver disease: a systematic review, Ann Intern Med, vol.161, pp.261-270, 2014. ,
Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study, Ann Intern Med, vol.156, issue.12, pp.841-848, 2012. ,
Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study ,
, Aliment Pharmacol Ther, vol.45, issue.7, pp.983-990, 2017.
Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups, Clin Gastroenterol Hepatol, vol.11, pp.95-101, 2013. ,
The metabolic syndrome-a new worldwide definition, Lancet, vol.366, pp.1059-62, 2005. ,
Sensitivity analyses for informative censoring in survival data: A trial example ,
, J Biopharm Stat, vol.27, issue.4, pp.595-610, 2017.
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine, J Hepatol, issue.17, pp.168-8278, 2017. ,
Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks, Clin J Am Soc Nephrol, vol.12, issue.7, pp.1181-1190, 2017. ,
Multiple imputation using chained equations: Issues and guidance for practice, Stat Med, vol.30, pp.377-99, 2011. ,
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement, BMJ, vol.162, pp.55-64, 2015. ,
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort), Hepatology, vol.62, pp.737-50, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01201948
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications, Gastroenterology, vol.152, pp.142-156, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01447065
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication, J Hepatol, vol.66, pp.485-93, 2017. ,
,
, Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3-and 6-month periodicities, Hepatology, vol.54, pp.1987-97, 2011.
Patients with Alcohol Compared to Hcv-Related Hepatocellular Carcinoma (HCC) Have a Reduced Survival, Results of a Nationwide Study, Hepatology, vol.62, p.399, 2015. ,
The clinical course of alcoholic cirrhosis: development of comorbid diseases. A Danish nationwide cohort study, Liver Int, vol.36, pp.1696-1703, 2016. ,
Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis, PLoS Med, vol.11, p.1001624, 2014. ,
, Bio-bank (serum, plasma, DNA) at